ProShare Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

ProShare Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,391	Closed	-$793K	–	1945
2023 Q1	$793K	Sell	7,391 -555	-7%	-$63.9K	﹤0.01%	771
2022 Q4	$874K	Buy	7,946 +1,132	+17%	+$73.4K	﹤0.01%	768
2022 Q3	$402K	Buy	+6,814	New	+$312K	﹤0.01%	991
2022 Q2	–	Sell	-9,650	Closed	-$365K	–	2230
2022 Q1	$365K	Sell	9,650 -2,318	-19%	-$91.6K	﹤0.01%	1499
2021 Q4	$474K	Buy	+11,968	New	+$375K	﹤0.01%	1490

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

ProShare Advisors's RXDX Position: Q2 2023 in Review

ProShare Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 7,391 shares — an estimated $793K sold.

ProShare Advisors first reported a position in RXDX in Q4 2021 and held it in 5 quarters. The position peaked at $874K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

ProShare Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
ProShare Advisors sold 7,391 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $793K.
ProShare Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
ProShare Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $874K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on ProShare Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.